Stay updated on Cabotegravir/Rilpivirine for Virologic Suppression Clinical Trial
Sign up to get notified when there's something new on the Cabotegravir/Rilpivirine for Virologic Suppression Clinical Trial page.

Latest updates to the Cabotegravir/Rilpivirine for Virologic Suppression Clinical Trial page
- ChecktodayChange DetectedThe page now shows a 403 Forbidden error, replacing the previous study record content with a generic error page. This blocks access to the NCT02938520 study details.SummaryDifference20%

- Check7 days agoChange DetectedThe page revision tag was updated from v3.6.6 to v3.7.0, representing a new version of the page for maintenance or updates.SummaryDifference0.0%

- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe page now shows a new revision tag: v3.6.6, replacing the previous v3.6.5, indicating a backend/document revision without altering the displayed study details.SummaryDifference0.0%

- Check28 days agoChange Detected2016 ( U.S. NIH Grant/Contract ) was added to the study's identifiers. This indicates NIH funding associated with the trial, but it does not alter the study content or user actions.SummaryDifference0.0%

- Check43 days agoChange DetectedA new revision entry v3.6.5 was added and the previous revision v3.6.4 was removed from the revision records, updating the page's version history.SummaryDifference0.0%

- Check50 days agoChange DetectedThe list of study locations now shows 108 sites across multiple countries, expanding from the prior 44 locations.SummaryDifference5%

Stay in the know with updates to Cabotegravir/Rilpivirine for Virologic Suppression Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabotegravir/Rilpivirine for Virologic Suppression Clinical Trial page.